China tightens medical device regulation; Covidien faces $180M in legal charges;

@FierceMedDev: Smith & Nephew partners with startup for knee surgical system. More | Follow @FierceMedDev

@StacyALawrence: FDA clears oral sleep apnea device, as search for CPAP alternatives continues. Story | Follow @StacyALawrence

@VarunSaxena2: Cohen: uterine sarcomas often don't cause symptoms; pathology needed for diagnosis, imaging helpful, but not always accurate. | Follow @VarunSaxena2

@MichaelGFierce: MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. Article | Follow @MichaelGFierce

@EmilyWFierce: San Francisco gynecologist steps down from FDA panel the day before power morcellator hearings. Story via The Wall Street Journal (sub. req.) | Follow @EmilyWFierce

> China revised laws regarding the illegal manufacturing and selling of medical devices in order to protect the rapidly growing industry. Violators can now be fined up to 20 times the value of the illegal device. More

> Dublin-based medical device maker Covidien ($COV) said it will take $180 million in legal charges for the third quarter due to pelvic mesh product litigation. Story

> Novartis ($NVS), owner of eye-care specialists Alcon Laboratories, announced plans to build $35 million global data center on Alcon's Fort Worth campus. The 10,000-square-foot project will be completed in fall 2015 and serve all Novartis Operations in North and South America. Article

Biotech News

@FierceBiotech: EuroBiotech: U.K. pols ready for $PFE's return, $AZN cozies up to EU academia, Israeli biotech upsizes IPO. Report | Follow @FierceBiotech

@JohnCFierce: Parting thought on $SRPT: Stock moves don't tell the whole story, folks. More | Follow @JohnCFierce

@DamianFierce: The "spinversion," a clever new way for companies to cut taxes but spare themselves the fallout of expatriation. Story via Bloomberg | Follow @DamianFierce

@EmilyMFierce: Ongoing Ebola outbreak sparks debate on experimental vaccine testing. Article from FierceVaccines | Follow @EmilyMFierce

> Sanofi's $1.5B dengue vaccine shows Phase III promise, but questions linger. More

> Sage's $60M swing is the next big test of biotech's IPO window. Story

Pharma News

@FiercePharma: Top-read on FierceVaccines yesterday: Could soaring vaccine prices spark Sovaldi-style payer pushback? Story | Follow @FiercePharma

@EricPFierce: Weak link in the supply chain. Pharmacist walks out of NY hospital with 1,500 oxycodone tabs. News | Follow @EricPFierce

@CarlyHFierce: Remember that time the NIH found smallpox samples? More | Follow @CarlyHFierce

> Questcor comes clean on adverse effects of beleaguered drug Acthar. Article

> Sun issues third recall since announcing deal to buy Ranbaxy. Story

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.